Anti-VEGF For The Management Of Proliferative Diabetic Retinopathy By Retinal Eye Specialists In 2023

Recent studies focused on the role of anti-VEGF injections in managing proliferative diabetic retinopathy, covering the effects of anti-VEGF on diabetic retinal neovascularization and vitreous hemorrhage. The study was a phase 2b noninferiority trial that compared intravitreal aflibercept to pan-retinal photocoagulation to manage proliferative diabetic retinopathy.

Those included in the study include patients over the age of eighteen with type 1 or 2 diabetes with clinical evidence of untreated proliferative diabetic retinopathy or persistent retinal neovascularisation after the initial PRP. These test subjects were divided into two groups, making up one hundred and nine patients.

The study showed that at fifty-two weeks there was a difference in visual acuity in the aflibercept group, which was superior to the PRP group by four letters. Five percent of the aflibercept group had ten or more letters of worsening compared to fifteen percent in the PRP group. The aflibercept group had four injections over fifty-two weeks, experiencing less vitreous hemorrhage. Macular thickness and volume increased in the PRP group with eighty-nine percent of the aflibercept group and seventy-one percent of the PRP ground having no macula edema by the fifty-second week.

The clarity studies showed that the eyes treated with aflibercept had a higher rate of regression of NVE when compared to the PRP group. This showed there can be a persistence of NVE and NVD even with a laser. This showed the potential of the injection therapy to benefit and induce regression in NV.

Ray Man, the PA for Mahi Muqit, a leading retinal eye specialist in London, UK, said “The study compared intravitreal ranibizumab therapy to PRP for treating proliferative diabetic retinopathy in patients over the age of eighteen with type 1 or 2 diabetes and one eye with PDR with no previous PRP. The study was carried out over a two-year period that showed peripheral visual field was worse and the eyes in the PRP group were more likely to require a vitrectomy. There was also a higher risk of retinal detachment in the PRP group.”

About Us:

Mahi Muqit is a leading consultant ophthalmologist, cataract, and vitreoretinal surgeon at two private clinics in London, United Kingdom. He provides patients with superior service and support with a range of surgical procedures to meet their eyesight requirements. He has built up a solid reputation for his eye services in the London area as an expert eye doctor and surgeon offering surgical retina, medical retina, and complex cataract surgery. He also offers surgery to patients suffering from diabetic retinopathy. Mahi Muqit is a member of the Royal College of Ophthalmologists, a member of the British and Eire Association of Vitreoretinal Surgeons, and the UK and Ireland Society of Cataract and Refractive Surgeons. To find out more, visit
https://www.retinasurgeon.uk.com/.